1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Dark Day At Idera As Tilsotolimod Fails To ILLUMINATE In Melanoma Study

Prospects Look Bleak

 
• By Kevin Grogan

The company's TLR-9 agonist has shown little to no benefit over BMS's Yervoy in patients with anti-PD-1 refractory advanced melanoma in a Phase III trial and Idera's stock has nosedived.

gloomy
Path ahead looks gloomy for tilsotolimod • Source: Shutterstock

Shares in Idera Pharmaceuticals, Inc. have taken a bashing after a late-stage trial showed that adding its investigational Toll-like receptor (TLR) 9 agonist tilsotolimod to Bristol Myers Squibb Company's CTLA-4 blocker Yervoy failed to improve outcomes in melanoma patients.

Idera's stock was trading down 65% after the markets closed on 18 March after results from the Phase III ILLUMINATE-301 trial of tilsotolimod in combination with Yervoy (ipilimumab) versus Yervoy alone in patients with anti-PD-1 refractory advanced melanoma did not meet its primary endpoint of objective response rate (ORR)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

More from R&D

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.